A medical cannabis product called RSHO-X dramatically reduced epileptic seizures in a Mexican study of Lennox-Gastaut syndrome, a severe form of childhood epilepsy that responds poorly to treatment.

The study covered 39 patients who had daily seizures despite being treated with at least three anti-epileptic drugs.

Seventeen percent of the participants had no seizures for at least four months, researchers said. Eighty-four percent had a 50 percent reduction in seizure activity. And more than half, 53 percent, saw their seizure activity drop by 75 percent.

“We are proud that our cannabidiol (CBD) hemp oil product, without THC, has enabled 17% of patients in the study to experience 100 percent relief from their seizures, the best results of any product/medication in the world regarding the reduction of seizures in Lennox-Gastaut patients,” Dr. Stuart Titus, CEO of Medical Marijuana, said in a press release.

Eighty-nine percent of the patients said their quality of life improved, according to the study. Increased alertness was reported by 43%, improved social interaction by 40%, and improved attention by 30%.

The children were treated with increasing doses of 5-7 mg per kg per day of RSHO-X, and were followed at least six months. The study noted no side effects of the treatment.

RSHO-X, or Real Scientific Hemp Oil-X, is a cannabidiol product that contains only trace amounts of THC, he psychoactive ingredient in cannabis.

The drug is marketed by Medical Marijuana, the first publicly traded cannabis company in the United States. The study was performed in collaboration with its subsidiary, HempMeds Mexico, and Dr. Saul Garza Morales, a neurologist at the National Institute of Perinatology in Mexico.

“It is exciting to see such widespread news coverage of these study results by the Mexico media, as studies that prove the therapeutic benefits of CBD [cannabidiol], like Dr. Garza’s study, will continue to help fuel less restrictive medical cannabis programs, not only in Mexico, but across the globe,” Titus said.

“In addition, as news spreads of this revolutionary treatment for diseases, such as epilepsy, more patients and families that suffer from debilitating medical conditions will receive help with medical marijuana,” he added.

Medical Marijuana said the study results will be published soon, but an abstract is already available on the company’s website.

Print This Page